Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITRIC: FMT for ICI-Refractory Cancer
NCT05286294Phase 2Active, not recruiting
- Sponsor
- Oslo University Hospital
- Start
- Jun 2022
- Primary completion
- Mar 2034
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fecal microbiome transplant in melanoma, head and neck squamous cell carcinoma (HNSCC), cutaneous squamous cell carcinoma (cSCC) and 3 more, sponsored by Oslo University Hospital. Primary endpoints: Safety evaluation of Fecal Microbiota Transplant (FMT) at 10 years and Tumor response evaluation at 10 years. Started Jun 2022; status: active, not recruiting.
02
Drugs
fecal microbiome transplant
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)cutaneous squamous cell carcinoma (cSCC)solid tumorclear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05286294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286294.